The ESR1 Mutations: From Bedside to Bench to Bedside
- 1 February 2021
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (3), 537-538
- https://doi.org/10.1158/0008-5472.can-20-4037
Abstract
The ESR1 ligand–binding mutations were unveiled a number of years ago and are the most common genetic mechanism of acquired resistance to endocrine treatment, particularly, to aromatase inhibitors. The discovery of these mutations was enabled after advancements in sequencing technologies and when metastatic tissue samples were interrogated. The ESR1 ligand–binding domain mutations are activating mutations that lead to constitutive ligand-independent activity, which explains the emergence of these mutations under the selective pressure of aromatase inhibitors. Arnesen and colleagues have generated new models of the ESR1 mutations using CRISPR technology to generate single-cell–derived clones in which the ESR1 ligand–binding mutations were “knocked-in” and expressed under the endogenous promoter of estrogen receptor. The authors have extensively characterized these models and have shed new light on the functional consequences ESR1 mutations. See related article by Arnesen et al., p. 539This publication has 10 references indexed in Scilit:
- Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary EffectsCancer Research, 2020
- ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosisBreast Cancer Research, 2020
- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancerAnnals of Oncology, 2020
- The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersCancer Cell, 2018
- Genetic and transcriptional evolution alters cancer cell line drug responseNature, 2018
- Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancernpj Breast Cancer, 2018
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancerNature Communications, 2018
- Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating MutationsCancer Cell, 2018
- The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast CancerCurrent Oncology Reports, 2017
- Activating ESR1 Mutations Differentially Affect the Efficacy of ER AntagonistsCancer Discovery, 2017